Efficacy of Yang Yin Sheng Xue formula against canine lymphoma chemotherapy-induced myelosuppression.

YYSXF may delay chemotherapy-induced myelosuppression in canine lymphoma, requiring larger studies.

This study evaluated Yang Yin Sheng Xue formula (YYSXF), a traditional Chinese medicine preparation, for treating chemotherapy-induced myelosuppression in canines with lymphoma. The research combined preclinical mouse models with a clinical pilot study. In the mouse model, cyclophosphamide-induced myelosuppression was treated with varying YYSXF concentrations. YYSXF treatment significantly improved peripheral blood cell counts (RBCs, WBCs, neutrophils, platelets), reduced bone marrow cell apoptosis, promoted cell cycle progression, and increased hematopoietic stem cell proportions. Histopathological analysis showed alleviation of bone marrow damage. The clinical component involved 11 dogs with multicentric lymphoma receiving either CHOP chemotherapy alone (control, n=6) or combined with YYSXF (test, n=5). Dogs receiving YYSXF showed significantly delayed onset of chemotherapy-induced CBC reductions, with decreases appearing after the eighth chemotherapy cycle versus the third cycle in controls. While promising, the authors acknowledge limitations including small sample size and the need for larger-scale validation before recommending YYSXF for routine clinical use in veterinary oncology.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.